GlucoTrack, Inc. (GCTK) Hisse Analizi
Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
GlucoTrack, Inc. (GCTK), Healthcare sektöründe faaliyet gösteriyor, son olarak $'dan işlem görüyor ve 0 piyasa değerine sahip.
Son analiz: 17 Mar 2026GlucoTrack, Inc. (GCTK) Sağlık ve Boru Hattı Genel Bakışı
GlucoTrack, Inc. develops and commercializes non-invasive glucose monitoring technology, primarily the GlucoTrack device, targeting the diabetes and pre-diabetes market in Israel and internationally. The company aims to offer a pain-free alternative to traditional blood glucose monitoring methods, positioning itself within the medical devices sector.
Yatırım Tezi
GlucoTrack, Inc. presents a focused investment opportunity within the medical device sector, specifically targeting the diabetes and pre-diabetes market with its non-invasive glucose monitoring technology. The company's value proposition centers on the GlucoTrack device, which aims to provide pain-free blood glucose level readings. Key value drivers include successful commercialization and adoption of the GlucoTrack device, expansion into new geographic markets, and potential partnerships with healthcare providers and distributors. The company's market capitalization is approximately $0.00 billion, with a P/E ratio of -0.04. Growth catalysts include positive clinical trial results, regulatory approvals in key markets, and increasing awareness of non-invasive glucose monitoring options. Potential risks include competition from established players in the glucose monitoring market, technological challenges in achieving accurate and reliable non-invasive measurements, and the company's limited financial resources.
FMP finansallarına ve nicel analizine dayanmaktadır
Temel Önemli Noktalar
- GlucoTrack, Inc. operates in the medical device industry, focusing on non-invasive glucose monitoring solutions.
- The company's primary product is the GlucoTrack device, designed for individuals with diabetes and pre-diabetes.
- GlucoTrack aims to provide a pain-free alternative to traditional blood glucose monitoring methods.
- The company's market capitalization is approximately $0.00 billion.
- GlucoTrack has a P/E ratio of -0.04.
Rakipler & Benzerleri
Güçlü Yönler
- Non-invasive glucose monitoring technology.
- Potential for pain-free blood glucose level readings.
- Focus on improving patient compliance.
- Proprietary GlucoTrack device.
Zayıflıklar
- Limited financial resources.
- Small team of employees.
- Dependence on a single product.
- Limited market presence.
Katalizörler
- Upcoming: Potential regulatory approvals in new geographic markets.
- Ongoing: Continued product development and innovation efforts.
- Ongoing: Strategic partnership discussions with healthcare providers and distributors.
Riskler
- Potential: Competition from established players in the glucose monitoring market.
- Potential: Technological challenges in achieving accurate and reliable non-invasive measurements.
- Ongoing: Limited financial resources.
- Potential: Market acceptance of non-invasive glucose monitoring technology.
Büyüme Fırsatları
- Expansion into New Geographic Markets: GlucoTrack has the opportunity to expand its commercial presence beyond Israel and into other international markets, including Europe, North America, and Asia. The global diabetes care devices market is estimated to reach billions of dollars, presenting a significant growth opportunity for GlucoTrack. Successful market entry and adoption of the GlucoTrack device in these regions could drive substantial revenue growth. The timeline for expansion depends on regulatory approvals, distribution partnerships, and market acceptance.
- Strategic Partnerships and Collaborations: GlucoTrack can pursue strategic partnerships with healthcare providers, diabetes clinics, and distributors to expand its reach and market penetration. Collaborations with established players in the diabetes care ecosystem could provide access to new customer segments and distribution channels. Such partnerships could accelerate the adoption of the GlucoTrack device and enhance its market visibility. The timeline for establishing strategic partnerships depends on negotiation and agreement with potential partners.
- Product Development and Innovation: GlucoTrack can invest in further product development and innovation to enhance the accuracy, reliability, and user-friendliness of its non-invasive glucose monitoring technology. Continuous improvement of the GlucoTrack device could strengthen its competitive advantage and attract a wider customer base. Future product development efforts could focus on integrating the device with mobile health platforms and developing advanced data analytics capabilities. The timeline for product development depends on research and development efforts and regulatory approvals.
- Direct-to-Consumer Marketing and Sales: GlucoTrack can implement a direct-to-consumer marketing and sales strategy to increase awareness and adoption of the GlucoTrack device among individuals with diabetes and pre-diabetes. Targeted marketing campaigns, online sales channels, and educational initiatives could drive customer acquisition and revenue growth. A direct-to-consumer approach could empower individuals to take control of their diabetes management and choose a non-invasive glucose monitoring option. The timeline for implementing a direct-to-consumer strategy depends on marketing budget and execution.
- Integration with Telehealth and Remote Monitoring Platforms: GlucoTrack can integrate its non-invasive glucose monitoring technology with telehealth and remote patient monitoring platforms to provide comprehensive diabetes management solutions. Integration with these platforms could enable healthcare providers to remotely monitor patients' glucose levels, provide personalized feedback, and improve patient outcomes. The increasing adoption of telehealth and remote monitoring presents a significant growth opportunity for GlucoTrack. The timeline for integration depends on technical development and partnerships with telehealth providers.
Fırsatlar
- Expansion into new geographic markets.
- Strategic partnerships with healthcare providers.
- Product development and innovation.
- Direct-to-consumer marketing and sales.
Tehditler
- Competition from established players.
- Technological challenges in achieving accurate non-invasive measurements.
- Regulatory hurdles.
- Market acceptance of non-invasive technology.
Rekabet Avantajları
- Proprietary non-invasive glucose monitoring technology.
- Patents protecting the GlucoTrack device.
- First-mover advantage in the non-invasive glucose monitoring market.
- Brand recognition associated with the GlucoTrack name.
GCTK Hakkında
GlucoTrack, Inc., formerly known as Integrity Applications, Inc., was founded in 2001 and is headquartered in Or Yehuda, Israel. The company focuses on the design, development, and commercialization of non-invasive glucose monitoring devices. Its primary product, the GlucoTrack device, is intended for use by individuals with diabetes and pre-diabetes, offering a method to obtain blood glucose level readings without the need for painful finger pricks. GlucoTrack aims to provide a more convenient and less invasive solution for glucose monitoring, potentially improving patient compliance and quality of life. The company's geographic focus includes Israel and international markets. GlucoTrack's evolution reflects a commitment to innovation in diabetes care, addressing the unmet needs of patients seeking alternatives to traditional glucose monitoring methods. The company changed its name to GlucoTrack, Inc. in November 2021, aligning its corporate identity with its core product. With a small team of 11 employees, GlucoTrack operates in the competitive medical device industry, striving to establish its non-invasive technology as a viable option for glucose management.
Ne Yaparlar
- Designs non-invasive glucose monitoring devices.
- Develops technology for pain-free blood glucose level readings.
- Commercializes GlucoTrack devices for people with diabetes and pre-diabetes.
- Offers an alternative to traditional blood glucose meters.
- Focuses on improving patient compliance and quality of life.
- Operates in the medical device industry.
İş Modeli
- Sells GlucoTrack devices to individuals with diabetes and pre-diabetes.
- Generates revenue through device sales and potential subscription services.
- Partners with distributors and healthcare providers to expand market reach.
Sektör Bağlamı
GlucoTrack, Inc. operates within the medical instruments and supplies industry, a segment of the broader healthcare sector. The industry is characterized by continuous innovation, driven by the increasing prevalence of chronic diseases like diabetes and the demand for more convenient and patient-friendly diagnostic and monitoring solutions. The global diabetes care devices market is expected to grow, fueled by the rising incidence of diabetes, technological advancements, and increasing awareness of diabetes management. GlucoTrack faces competition from established players offering traditional blood glucose meters and continuous glucose monitoring systems. The company's success depends on its ability to differentiate its non-invasive technology and capture market share in the growing diabetes care market.
Kilit Müşteriler
- Individuals with diabetes.
- Individuals with pre-diabetes.
- Healthcare providers.
- Diabetes clinics.
Finansallar
Grafik & Bilgi
GlucoTrack, Inc. (GCTK) hisse senedi fiyatı: Price data unavailable
Son Haberler
-
12 Health Care Stocks Moving In Monday's Intraday Session
benzinga · 30 Mar 2026
-
GlucoTrack Stock Gains As Data Backs FDA Filing Plans For Glucose Monitoring Tech
benzinga · 27 Mar 2026
-
12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga · 29 Oca 2026
-
12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga · 28 Eki 2025
Analist Konsensüsü
Fikir Birliği Derecelendirmesi
GCTK için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.
Fiyat Hedefleri
GCTK için Wall Street fiyat hedefi analizi.
MoonshotScore
Bu puan ne anlama geliyor?
MoonshotScore, GCTK'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.
Rakipler & Benzerleri
Son Haberler
12 Health Care Stocks Moving In Monday's Intraday Session
GlucoTrack Stock Gains As Data Backs FDA Filing Plans For Glucose Monitoring Tech
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
Yönetim: Paul V. Goode
CEO
Paul V. Goode serves as the CEO of GlucoTrack, Inc. His background includes experience in managing and leading teams, as evidenced by his current role overseeing 11 employees. Further details regarding his career history, education, and previous roles are not available in the provided data.
Sicil: Information regarding Paul V. Goode's specific achievements, strategic decisions, and company milestones under his leadership at GlucoTrack, Inc. is not available in the provided data.
GlucoTrack, Inc. Hissesi: Cevaplanan Temel Sorular
GCTK için değerlendirilmesi gereken temel faktörler nelerdir?
GCTK'ı değerlendirmek, temelleri, analist konsensüsünü ve risk faktörlerini gözden geçirmeyi içerir. Temel güçlü yan: Non-invasive glucose monitoring technology.. İzlenmesi gereken birincil risk: Potential: Competition from established players in the glucose monitoring market.. Bu bir finansal tavsiye değildir.
GCTK MoonshotScore'u nedir?
MoonshotScore, GCTK'ı finansal sağlık, piyasa momentumu ve risk faktörleri genelinde 0 ile 100 arasında derecelendirir. 70'in üzerindeki puanlar daha yüksek derecelendirmeleri, 50-70 arası orta ve 50'nin altı daha düşük derecelendirmeleri gösterir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.
GCTK verileri ne sıklıkla güncellenir?
GCTK fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.
Analistler GCTK hakkında ne diyor?
GCTK için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.
GCTK'a yatırım yapmanın riskleri nelerdir?
GCTK için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Competition from established players in the glucose monitoring market.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.
GCTK'ın P/E oranı nedir?
GCTK için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için GCTK'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.
GCTK aşırı değerli mi, yoksa düşük değerli mi?
GlucoTrack, Inc. (GCTK)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.
GCTK'ın temettü verimi nedir?
GlucoTrack, Inc. (GCTK) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.
Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.
Resmi Kaynaklar
Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.
- Limited financial data available.
- AI analysis pending for GCTK.